Next Science Ltd (ASX: NXS) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Next Science Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $84.59 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 291.70 million
Earnings per share -0.070
Dividend per share N/A
Year To Date Return -14.71%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Next Science Ltd (ASX: NXS)
    Latest News

    a woman
    Share Market News

    Why this ASX medical technology share is up 11% today

    The Next Science Ltd (ASX:NXS) share price is racing higher today, following the release of an update regarding the coronavirus…

    Read more »

    a woman
    Share Gainers

    Why BHP, Fisher & Paykel Healthcare, Northern Star, & Next Science are racing higher

    BHP Group Ltd (ASX:BHP) and Fisher & Paykel Healthcare Corp Ltd (ASX:FPH) shares are two of four racing higher on…

    Read more »

    a woman
    Share Gainers

    Why Clinuvel, Coles, Flight Centre, & Next Science are racing higher

    Coles Group Ltd (ASX:COL) and Flight Centre Travel Group Ltd (ASX:FLT) shares are two of four racing higher on Tuesday.…

    Read more »

    a woman
    Share Gainers

    Why the Next Science share price is storming 15% higher

    The Next Science Ltd (ASX:NXS) share price is surging higher on Tuesday after the release of a positive announcement...

    Read more »

    a woman
    Share Market News

    Here's why Costa, Perenti and Next Science shares are moving higher

    Despite the S&P/ASX 200 Index (INDEXASX:XJO) facing its sixth straight day of losses, here's why these 3 ASX shares are…

    Read more »

    a woman
    Share Gainers

    Why this ASX medical technology share is pushing higher today

    The Next Science Ltd (ASX:NXS) share price has defied the market selloff and pushed higher on Friday. Here's why...

    Read more »

    a woman
    Share Market News

    Why the Next Science share price has surged more than 6% today

    The Next Science share price has surged more than 6% following the company's signed distribution agreement in the US.

    Read more »

    a woman
    Share Gainers

    Why Cann, Next Science, Service Stream, & Village Roadshow are pushing higher

    The Service Stream Limited (ASX:SSM) share price and the Village Roadshow Ltd (ASX:VRL) share price are two of four pushing…

    Read more »

    a woman
    Share Gainers

    Why the Next Science share price is racing higher today

    The Next Science Ltd (ASX:NXS) share price is racing higher on Friday after being granted a patent in the United…

    Read more »

    a woman
    Share Market News

    Why the Paradigm share price is up 250% in 2019

    Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares are up from 99 cents on New Year's day 2019 to $3.49 today and…

    Read more »

    a woman
    Share Market News

    The Next Science share price is tanking on a trading update

    Will Next Science turn into a 'multi bagger' for investors? It alreadsy has four anti-bacterial FDA-approved products used in surgery.

    Read more »

    a woman
    Share Market News

    Why the Novita Healthcare share price is now up 350% in 3 days

    Novita shows how penny stocks can offfer incredible gains in percentage terms. However, penny stocks are risky.

    Read more »

    NXS ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Next Science Ltd

    Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.

    NXS Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    19 Jul 2024 $0.29 $0.01 3.57% 119,238 $0.28 $0.30 $0.28
    18 Jul 2024 $0.28 $0.01 3.70% 259,041 $0.27 $0.28 $0.25
    17 Jul 2024 $0.27 $0.02 8.00% 445,928 $0.26 $0.27 $0.23
    16 Jul 2024 $0.25 $-0.01 -3.85% 95,914 $0.26 $0.27 $0.25
    15 Jul 2024 $0.26 $0.02 8.33% 142,414 $0.25 $0.26 $0.24
    12 Jul 2024 $0.24 $0.02 8.89% 65,991 $0.23 $0.25 $0.23
    11 Jul 2024 $0.23 $0.02 9.76% 251,164 $0.22 $0.23 $0.22
    10 Jul 2024 $0.21 $0.00 0.00% 35,295 $0.21 $0.21 $0.20
    09 Jul 2024 $0.21 $-0.01 -4.76% 16,209 $0.21 $0.21 $0.20
    08 Jul 2024 $0.21 $0.00 0.00% 8,631 $0.21 $0.21 $0.20
    05 Jul 2024 $0.21 $0.02 10.26% 17,754 $0.20 $0.21 $0.20
    04 Jul 2024 $0.20 $-0.02 -9.52% 342,897 $0.21 $0.21 $0.20
    03 Jul 2024 $0.21 $-0.01 -4.65% 169,240 $0.22 $0.22 $0.21
    02 Jul 2024 $0.22 $-0.01 -4.55% 26,696 $0.22 $0.23 $0.22
    01 Jul 2024 $0.22 $-0.02 -8.51% 53,550 $0.22 $0.24 $0.22
    28 Jun 2024 $0.24 $0.01 4.44% 206,333 $0.22 $0.24 $0.22
    27 Jun 2024 $0.23 $0.00 0.00% 113,093 $0.22 $0.23 $0.22
    26 Jun 2024 $0.23 $0.00 0.00% 720,081 $0.22 $0.24 $0.22
    25 Jun 2024 $0.23 $0.02 9.52% 363,809 $0.22 $0.25 $0.22
    24 Jun 2024 $0.21 $-0.04 -16.33% 559,256 $0.25 $0.26 $0.21

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    14 Jun 2024 Harry Hall(IV) Issued 1,395,393 $348,848
    Issue of securities. 1,395,393 Sign-on Rights
    01 Nov 2023 Harry Hall(IV) Issued 200,000 $54,440
    Placement.
    01 Nov 2023 Grant Hummel Issued 309,524 $130,000
    Placement.
    01 Nov 2023 Aileen Stockburger Issued 524,801 $220,416
    Placement.
    31 Jul 2023 Judith Mitchell Transfer 420,000 $220,500
    Off-market transfer. Assuming off-market transfer of shares
    31 Jul 2023 Judith Mitchell Transfer 420,000 $220,500
    Off-market transfer. Assuming off-market transfer of shares

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Grant Hummel Non-Executive Director Aug 2023
    Mr Hummel was part of Next Science's ASX listing deal team in 2019. He has been a partner of a major Australian law firm, for over fifteen years. Grant has experience with corporate and commercial transactions, with particular expertise in advising primary care, allied health, medical device and life science clients.
    Ms Aileen Stockburger Non-Executive DirectorNon-Executive Chairman Oct 2018
    Mr Stockburger was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Aileen led Johnson & Johnson's efforts to acquire Synthes for approximately $21 billion, Johnson & Johnson's medical device acquisition. She also led the efforts to drive the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also involved in numerous other M&A transactions including Pfizer Consumer Healthcare, Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena. He held dirctorships in Microbot Medical Inc. as Non Executive Director from last 3 years. He is Member of Risk, People & Culture Committee.
    Ms Katherine (Kathy) Ostin Non-Executive Director Oct 2023
    Ms Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has experience in aged care and healthcare sectors, having established and led KPMG's New South Wales Health, Ageing and Human Services audit practice from 2006 to 2017. During her 24 years with KPMG, Kathy worked in Australia, the US, Asia, and the UK. She is Chair of Risk Committee.
    Mr Harry Thomas Hall(IV) Chief Executive OfficerManaging Director Jul 2023
    Mr Hall has more than 28 years' experience in the global medical device industry and has held diverse general management roles including product development, global strategic marketing, commercial operations, and sales leadership. Prior to joining Next Science, He was a member of the Global Leadership Team and R&D Leadership Team for DePuy Synthes, a subsidiary of Johnson and Johnson (NYSE:JNJ), and completed the launch of the first surgical robot developed by JNJ / DePuy Synthes. He joined DePuy Synthes in 1997 where he held senior roles including Global Vice President - MedTech R&D and Worldwide President - Trauma, Extremities, Craniomaxillofacial & Animal Health. As Worldwide President of Trauma, Extremities, Craniomaxillofacial and Animal Health, He was responsible for a global portfolio and execution strategy for a US$3.2bn platform including upstream marketing and commercial planning in the Global Orthopaedic Unit of DePuy Synthes. In addition to managing over 1,100 staff across sales, marketing and R&D, He created and sustained personal relationships with well over one hundred key opinion leaders worldwide.
    Ms Gillian Maria Nairn Company Secretary Jun 2018
    -
    Gillian Maria Nairn Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 59,990,423 20.57%
    Auckland Trust Company Ltd <Second Pacific Master Superannuation Fund> 56,019,938 19.20%
    Ubs Nominees Pty Ltd 16,528,388 5.67%
    Hsbc Custody Nominees (Australia) Limited A/C 2 11,839,023 4.06%
    Mr Charles Robert Dirck Wittenoom 5,118,880 1.75%
    Judith Lee Mitchell 4,706,975 1.61%
    Dr Matthew Franco Myntti 4,171,824 1.43%
    Citicorp Nominees Pty Limited 3,815,931 1.31%
    Mr James Fong Seeto 3,000,000 1.03%
    Bnpp Noms Pty Ltd Hub24 Custodial Serv Ltd 2,925,007 1.00%
    J P Morgan Nominees Australia Pty Limited 2,921,688 1.00%
    S G Andrew Pty Ltd <S G Andrew Super Fund A/C> 2,745,000 0.94%
    Mr Dean Anthony Mackenzie 2,514,258 0.86%
    Bond Street Custodians Limited <Lam1 D08047 A/C> 2,460,427 0.84%
    Mr Evan Philip Clucas & Ms Leanne Jane Weston<Kuranga Nursery Super A/C> 2,251,187 0.77%
    Belgravia Strategic Equities Pty Ltd 1,965,000 0.67%
    Twenty Fifth Elporto Pty Ltd <Twenty Fifth Elporto Sf A/C> 1,800,000 0.62%
    Brook St Smsf Pty Ltd <Brook St Smsf A/C> 1,255,702 0.43%
    Retzos Executive Pty Ltd <Retzos Executive S/Fund A/C> 1,057,146 0.36%
    Mr Timothy Ian Douglas 1,032,075 0.35%

    Profile

    since

    Note